Mr. Finley is an experienced financial executive, having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal Chief Financial Officer (CFO) and an independent investment banker. Prior to joining Palisade Bio (formerly Leading BioSciences) as the company’s CFO, Mr. Finley was the Chief Executive Officer, President and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was a Principal and CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as Executive Vice President and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. Mr. Finley began his business career as a tax specialist with Deloitte & Haskins and Sells (now Deloitte LLP), and later was co-owner of Mitchell Finley & Company, a full-service accounting firm.

Mr. Finley earned a Bachelor’s degree in Business Administration from Boise State University and a Master’s degree in Taxation from the University of Denver.

Dr. Mitch Jones is an accomplished physician and executive with extensive experience in the development of innovative therapeutics for inflammatory and fibrotic diseases. As Chief Medical Officer at Palisade Bio, Dr. Jones oversees all clinical development programs, regulatory strategies, and medical affairs, ensuring the advancement of the company’s pipeline in inflammatory, autoimmune and fibrotic disease.

Dr. Jones has a distinguished track record of advancing innovative therapies from translational research through clinical development and achieving regulatory approvals. He most recently served as Vice President of Corporate Development & Strategy at Chemomab Therapeutics, where he directed corporate strategy, program development, and strategic partnerships. His efforts were instrumental in advancing Chemomab’s clinical-stage programs and supporting the company’s financing and M&A activities.

Prior to Chemomab, Dr. Jones held key leadership roles at Finch Therapeutics and Biora Therapeutics (formerly Progenity). At Finch Therapeutics, he was Vice President of Clinical Discovery and Development, contributing to the company’s IPO and the early clinical development of novel therapeutics for IBD, chronic hepatitis B, and solid tumor immunotherapy. At Biora Therapeutics, he served as Vice President of Innovation and Clinical Translational Development, where he lead the development of the company’s technology platforms including Navicap™ and Biojet™, executed early clinical development and proof of efficacy studies, created strategic roadmaps and played a pivotal role in securing $125 million in venture financing and leading the company through its IPO. His early role within the company was building the GI therapeutics division as Vice President of Translational and Clinical Development.

Dr. Jones founded Interface Therapeutics, where he developed a novel sampling platform for multi-omics analysis of GI tract samples, leading to the discovery of locally acting therapeutics for IBD. Interface Therapeutics was later acquired by Biora Therapeutics. Earlier in his career, he founded Micropharma, where he developed the FDA-approved product LRC™, now sold globally by Chr. Hansen, and achieved regulatory approvals for microbiome-based therapeutics for metabolic and inflammatory diseases.

Dr. Jones is an inventor on nearly 200 patents and has authored numerous scientific publications. He holds MD and PhD degrees.

Mr. Willie has served as Senior Vice President, Finance and Corporate Controller of Palisade Bio since February of 2023 and previously served as Vice President, Finance and Corporate Controller. Prior to joining Palisade Bio, Mr. Willie held various senior roles at PricewaterhouseCoopers, LLP where he provided key assurance services to clinical-stage biotechnology companies as they navigated the complexities of international collaborations, clinical trials, and follow-on offerings.

Mr. Willie earned a Master’s degree in Accountancy and Bachelor’s degree in Accounting from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

Dr. Joerg Heyer is an accomplished leader in Translational Science, Translational Medicine, and Clinical Research with over two decades of experience in the pharmaceutical industry. As the Head of Translational Science and Medicine, Dr. Heyer has demonstrated exceptional expertise in guiding drug development from preclinical stages through to clinical trials. Dr. Heyer has played a pivotal role in the successful development and strategic management of multiple drug programs, including the oncology drug tivozanib and an infectious disease treatment, CP101. Dr. Heyer’s career is distinguished by his contributions to biomarker strategy and assay development, where he has developed and validated numerous clinical biomarker assays and led innovative strategies for integrating standardized assays into clinical trials. His preclinical research achievements include pioneering chimeric mouse models and devising novel dosing strategies, which have been instrumental in advancing targeted therapies and securing major pharmaceutical partnerships. Dr. Heyer has held senior leadership positions at Dynamicure, Finch Therapeutics, and AVEO Pharmaceuticals, among others, where he has successfully managed multi-million-dollar collaborations and built high-performing teams across international sites.

Dr. Heyer’s academic credentials include a Ph.D. from the University of Wuerzburg and postdoctoral research at the Albert Einstein College of Medicine. Dr. Heyer’s extensive publication record and his role as a sought-after speaker at prestigious international conferences underscore his influential contributions to the field.